This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
GVAX Lung Cancer Vaccine
Drug Names(s): BioSante Lung Cancer Vaccine
Description: GVAX lung cancer vaccine is a patient-specific vaccine designed to induce a systemic immune response against the patient's lung cancer. After surgical removal of a patient's tumor, the GVAX cancer vaccine is prepared by culturing and genetically modifying the patient's tumor cells to secrete GM-CSF, an immune stimulatory hormone. The cells are then irradiated for safety prior to vaccinating the patient.
Cell Genesys and Japan Tobacco
In October 2002, Cell Genesys announced that it had reacquired full commercial rights to GVAX lung cancer vaccines following the termination of its remaining license agreement with the pharmaceutical division of Japan Tobacco (JT). Cell Genesys now holds all worldwide commercial rights to its entire portfolio of GVAX cancer vaccine products. This agreement was originally signed in December 1998 and later modified in November 2001 to focus only on GVAX lung cancer vaccines. As of December 31, 2002, Cell Genesys has received over $81 million in milestone and other payments and reimbursement for research and development costs. This was the second collaboration agreement between Cell Genesys and JT. The first collaboration, signed in 1991, funded the successful development of the fully human monoclonal antibody technology transferred to Abgenix.
Cell Genesys and BioSante
In June 2009, BioSante Pharmaceuticals and Cell Genesys...See full deal structure in Biomedtracker
Partners: Japan Tobacco Inc. ANI Pharmaceuticals, Inc.
GVAX Lung Cancer Vaccine News
Additional information available to subscribers only: